Introduction
Patients with insulin-dependent diabetes mellitus (IDDM) ' possess antibodies to multiple islet cell antigens including insulin, the 65-kD isoform of glutamate decarboxylase (GAD), and carboxypeptidase H ( 1) . In our laboratory we have been characterizing protein autoantigens in IDDM that are detected on SDS- 1 . Abbreviations used in this paper: 37k and 40k antigens, 37,000-and 40,000-Mr proteolytic fragments; GAD, glutamate decarboxylase; IA2ic, intracellular domain of IA-2; ICA, islet cell antibody; IDDM, insulin-dependent (type 1) diabetes mellitus.
PAGE as diffuse 64,000-Mr bands but cleaved by trypsin to 37,000-and 40,000-M, proteolytic fragments (37k and 40k antigens) (2) . Antibodies to these antigens are found in up to 80% of recent onset IDDM patients and are very closely associated with diabetes development in identical twins (3) and first-degree relatives of IDDM patients (4) , in patients with polyendocrine autoimmunity or stiff-man syndrome (5) , and in islet cell antibody (ICA)-positive schoolchildren (6) . These antibodies should be particularly useful in identifying individuals at risk for IDDM who might be candidates for disease prevention protocols.
Identification of the 37k and 40k antigens is essential for the development of better assays for antibodies to the proteins for screening purposes and to assess the role of the antigens in disease pathogenesis. The antigens are expressed at low levels in pancreatic islets and insulinoma cells, and our attempts to purify sufficient quantities of protein for amino acid sequencing or antibody production have not been successful. As an alternative approach, we have compared the physical and antigenic properties of the proteins with potential autoantigens identified in other studies. We now report that the 37,000-and 40,000-Mr fragments are derived from different, but probably related, protein precursors. Furthermore, we demonstrate that the 40,000-Mr fragments are related to a protein designated IA-2 (7) , which is homologous to members of the receptor-linked family of protein tyrosine phosphatases and which shares sequence identity with a cloned target for antibodies in human IDDM, ICA512 (8) .
Methods
Sera. Sera from recent onset IDDM patients, from first-degree relatives of IDDM patients, and from healthy controls, previously characterized for antibodies to islet 64,000-Mr proteins, to GAD, and to tryptic fragments of islet antigen were selected from previous studies on autoantigens in IDDM (3, (9) (10) (11) .
Islets and cell lines. Islets were isolated from 5-7-day-old newborn Wistar rats as described (12) . The rat insulinoma cell line subclone RIN-5AH (13) Chalfont, UK) as described (9) . cDNA cloning and expression. RNA was extracted from human fetal brain (gift of Dr. Kate Langford, King's College School of Medicine and tion sites for BamHI and EcoRI, respectively. Reamplification products were ligated into the BamHI and EcoRI sites of the vector pGEM 4Z (Promega Corp., Madison, WI). DNA sequence corresponding to the intracellular domain of IA-2 (IA-2ic) was amplified from human islet cDNA using the primer sequences: 5 '-ATGCAGCAAGACAAGGAG-CGCCTG-3' and 5'-TCACTGGGGCAGGGCCTTGAG-3'. Amplification products were cloned directly into the vector pGEM-T (Promega) and subcloned into pGEM 4Z and PinPointlm (Promega).
A 3.5-kb cDNA containing the coding region for the rat homologue of the IA-2 molecule was obtained by screening a rat brain cDNA library in X-ZAP (Stratagene Ltd., Cambridge, UK) with the human ICA512 DNA segment. The cDNA was subcloned into pGEM 1 lZ (Promega). A 5.3-kb cDNA for the 65-kD isoform of rat GAD was also cloned from the rat brain library by screening with a 346-bp rat GAD65 DNA segment generated by DNA amplification. The coding region for rat GAD65 was amplified from the 5.3-kb cDNA using specific primers and cloned into pGEM 4Z.
Nucleotide sequences of cloned products were verified by automated sequencing using a sequencer (ABI 373A; Applied Biosystems Inc., Foster City, CA). ICA512, IA-2ic, and GAD sequences in pGEM 4Z or pGEM 1 1Z were transcribed and translated in vitro in the presence of [351 ]methionine (Amersham) using the TNTh-coupled reticulocyte lysate system (Promega). IA-2ic was also expressed in Escherichia coli as a fusion protein with a biotin-labeled peptide sequence at the NH2 terminus using the PinPoint' expression system. Bacteria were lysed by stirring with lysozyme (1 mg/ml) in 150 mM NaCl, 10 mM Hepes, pH 7.4, followed by addition of Triton X-100 (0.1% vol/vol) for 5 min and DNase (20 U/ml) for 5 min. Particulate material was sedimented by centrifugation at 10,000 g for 15 min. The expressed fusion protein was purified from lysates by affinity chromatography on streptavidinpolymethacrylate (Soft LinkTm, Promega) columns. Protein was eluted with 5 mM biotin, which was subsequently removed by dialysis against 1 mM sodium phosphate, pH 7.4. The purified IA-2ic fusion protein resolved on SDS-PAGE as a single Coomassie brilliant blue-stained band with an Mr of 59,000.
Immunoprecipitation. Radiolabeled islets or insulinoma cells were extracted in Triton X-1 14 and subject to detergent-phase separation as previously described (2) . Rat Eluates were subjected to immunoprecipitation with sera positive and negative for antibodies to 37k antigen as described above.
Database searches. Searches of the GenBank DNA sequence database and DNA sequence analyses were performed with the University of Wisconsin Genetics Computer Group programs (14) .
Statistical analysis. The degree of correlation among antibody measurements on serum samples was determined by linear regression analysis.
Results
Binding of antibodies from relatives of IDDM patients to 37,000-and 40,000-Mr fragments of antigen. We have previously reported a strong correlation between the presence of antibodies to 37,000-and 40,000Mr fragments of antigen in sera from IDDM patients ( 15 ). These results suggested that the proteolytic fragments have similar antigenic properties and may be derived from the same or related proteins. However, analysis of binding of antibodies in sera of nondiabetic relatives of IDDM patients has revealed differences in antibody reactivity to the two fragments. Thus, in addition to sera that contain antibodies to both 37,000-and 40,000-Mr fragments, sera were identified that contain antibodies only to the 40,000-Mr fragments ( Fig. 1 A) . These results suggest that there may be differences in the antigenic properties of these antigenic fragments and that they may not necessarily be derived from the same protein.
Binding of precursors to the 37,000-and 40,000-Mr frag- recovered in eluates of wheat germ agglutinin columns (specificity N-acetyl glucosamine) whereas those of 37,000Mr fragments were absent (Table I) . Precursors of 37,000-M, fragments were recovered in eluates of lentil lectin columns (see Table I , mannose specificity). These results demonstrate that these autoantigens are glycoproteins and that the precursors to the 37,000-and 40,000-Mr fragments have different carbohydrate content.
Correlation ofantibodies to 40,000-Mrfragments with antibodies to ICA512 and IA-2. Screening of islet cDNA libraries with sera from IDDM patients has recovered cDNA for a number of potential IDDM-associated autoantigens, including a clone designated ICA512, that contains a domain homologous to protein tyrosine phosphatases (8) . Analysis of the predicted amino acid sequence of this protein revealed a number of similarities with the 37k and 40k antigens, including a predicted molecular mass of -60 kD, the presence of potential N-glycosylation sites, and a putative transmembrane domain, consistent with the known amphiphilic properties of the 37k-and 40k-antigens (2) . A segment of cDNA containing the reported antibody binding site on ICA512 (Fig. 2) (Fig. 1 B) . All sera that immunoprecipitated the protein were found to be positive for antibodies to 40,000Mr fragments of islet autoantigen. How cluding sera negative for antibodies to the 37,000Mr fragment (Fig. 1 C) . Similar results were obtained for the complete rat IA-2 molecule. Furthermore, a strong correlation between levels of antibodies to IA-2ic and the 40,000-Mr fragments was observed (r = 0.85; P . 0.001; Fig. 3 ). No association between antibodies to IA-2ic and antibodies to GAD was detected ( Fig.   1 D) . These results demonstrate that the 40,000-Mr fragments share similar antigenic properties with the putative cytoplasmic domain of IA-2. Sera containing antibodies to IA-2ic immunoprecipitate 64,000-Mr protein from islet extracts. We have previously shown that the 37,000-and 40,000-Mr fragments are derived from proteins that are resolved as diffuse bands of Mr 64,000 on SDS-PAGE and that are distinct from GAD (2). We therefore investigated whether the presence of antibodies to IA-2ic in recent onset diabetic patients' sera was associated with the ability to immunoprecipitate 64,000-Mr proteins from islet extracts. Sera were also tested for the presence of antibodies to GAD. Antibodies in sera from IDDM patients immunoprecipitated 64,000-Mr proteins that were resolved as both sharp and diffuse bands on SDS-PAGE ( Fig. 4 A) ; diffuse 64,000-Mr bands were detected in patients with high levels of antibodies to IA-2ic (Fig. 4 A, lanes 1, 5, 7 , and 9) whereas sharp 64,000-Mr bands were associated with the presence of high levels of GAD antibodies (e.g., Fig. 4 A, lanes 4, 11, and 13 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 (Fig. 5 A) . The IA-2ic preparation also blocked autoantibody binding to human IA-2ic (Fig. 5 B) and to the complete rat IA-2 molecule (Fig. 5 C) expressed by in vitro transcription and translation but had no effect on binding to GAD65 (Fig. 5 D) . These results further confirm the similar antigenic properties of IA-2 and the 40k-antigen. Trypsinization of IA-2 generates 40,000-Mr fragments. Experiments were performed to determine whether trypsin treatment of IA-2 generates proteolytic fragments of similar size to those of native 37k-or 40k-antigen. Radiolabeled human IA2ic and the complete rat IA-2 molecule were obtained by in vitro transcription and translation. Translated proteins were incubated with sera from IDDM patients and immunoprecipitated proteins either run directly on SDS-PAGE or treated with trypsin (0.1 mg/ml) for 20 min on ice before gel electrophoresis. The mobility on SDS-PAGE of the proteolyzed immunoprecipitates was compared with that of similarly treated immunoprecipitates with RIN cells as source of 37k-antigen. Trypsin cleavage of both IA-2ic and the complete IA-2 protein generated a major fragment with identical mobility to the 40,000-M, fragment of insulinoma antigen (Fig. 6) . Fragments of 37,000 Mr were not generated under these conditions. (17) . Whether IA-2 (ICA512) has a very restricted substrate specificity or whether it is inactive as a tyrosine phosphatase remains to be determined. In our initial studies on antibody binding to IA-2 and ICA512 we used protein expressed by a cloned cDNA encoding the reported protein sequence of ICA512-1, a region of the molecule known to contain the antibody binding domain (8) . However, owing to a probable error in the ICA512 sequence, this protein has a COOH terminus truncated by 20 amino acid residues. We subsequently cloned the entire intracellular domain of IA-2, encoding a protein fragment (IA-2ic) 60 amino acids longer than our ICA512 product. Virtually all sera positive for antibodies to 40,000Mr fragments bound to IA-2ic, and a strong correlation between antibody levels was detected. Approximately 50% of sera positive for antibodies to IA-2ic also bound the shorter ICA5 12 polypeptide, showing that this region contains epitopes for some, but not all, of these diabetes-associated antibodies and revealing heterogeneity between patients in the epitopes recognized.
The (20) (21) (22) , but whether this is a feature of IA-2-related phosphatases is not known. Clearly, amino acid sequence data on the precursor to 40,000-Mr fragments are required to define the precise relationship of this antigen to IA-2.
We have previously shown that antibodies in IDDM patients' sera to 37,000Mr fragments are strongly correlated with those to 40,000-Mr fragments (15) , suggesting that these are antigenically similar. However, data presented here identify antibodies in sera from nondiabetic relatives that can distinguish between the two fragments ( Fig. 1 A) . The precursors can also be separated by binding to immobilized lectins, indicating that these have different carbohydrate contents. Trypsinization of IA-2ic or the complete IA-2 protein did not generate 37,000-Mr fragments. However, recombinant IA-2ic was able to block autoantibody binding to 37,000-M fragments, although with some sera blocking was incomplete. These observations indicate that the 37,000-Mr fragments are unlikely to be derived from IA-2, although the ability of IA-2ic to block autoantibody binding to the fragments does suggest that the antigen is structurally similar to another member of the protein tyrosine phosphatase family.
A number of potential islet cell antigens have been identified by screening of islet cDNA libraries with IDDM patients' sera, including carboxypeptidase H and ICA 69 (23, 24) . However, to date, these have not corresponded to antigens detected by analysis of antibody reactivity with proteins in islet extracts, and the expressed recombinant proteins do not always show reactivity with patients' sera in immunoprecipitation reactions (25) . Neither GAD nor insulin have been identified by the library screening approach. Diabetes-associated antibodies to these antigens are known to bind epitopes that are highly dependent on protein conformation (26, 27) , and these may not be displayed by the library. If the 40,000-M, fragments of islet antigen are indeed equivalent to IA-2 and ICA512, then this protein will represent a rare case of an islet antigen identified by both immunochemical and molecular biological approaches. We have shown in different populations that antibodies to the 37k and 40k antigens are very closely associated with diabetes development (3) (4) (5) (6) . The finding that the 40,000-M, fragments of this antigen are related to the cloned proteins IA-2 and ICA5 12 will simplify assessment of the predictive value of these antibodies in larger populations. Furthermore, the availability of suitable amounts of recombinant antigen will allow studies to define the role of the protein in pathogenesis of disease and in its potential use in disease prevention therapies.
